| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 益方生物科技（上海）股份有限公司是一家立足中国具有全球视野的创新型药物研发企业，聚焦于肿瘤、代谢性疾病等重大疾病领域。公司以解决尚未满足的临床需求为理念，致力于研制出具有自主知识产权、中国创造并面向全球的创新药物，持之以恒地为患者提供更加安全、有效、可负担的治疗方案。 益方生物由王耀林（YaolinWang）等多位海归博士联合创办，核心研发团队平均拥有超过20年跨国制药公司主持新药研发和团队管理的丰富经验。益方生物凭借对疾病作用机理的深入研究和理解，选择具有潜力的药物靶点，从化合物与靶点的结合构象出发设计药物，在对疾病实现精准治疗的同时，确保优异的人体安全性。基于出众和丰富的药品开发实力和经验，益方生物自主研发了一系列具有专利保护的创新型靶向药物，覆盖非小细胞肺癌、乳腺癌、结直肠癌等实体瘤，以及高尿酸血症及痛风等代谢性疾病。 | ||||||||||||||||||||||||
| Main Business | 创新药物的研发、生产和销售 | ||||||||||||||||||||||||
| Legal Representative | 王耀林 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 江岳恒 | ||||||||||||||||||||||||
| Solicitors | 北京市君合律师事务所 | ||||||||||||||||||||||||
| Auditors | 普华永道中天会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 021-50778527 | ||||||||||||||||||||||||
| Fax No | 021-50778527 | ||||||||||||||||||||||||
| Website | www.inventisbio.com | ||||||||||||||||||||||||
| ir@inventisbio.com | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 25/07/2022 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ -0.490 | ||||||||||||||||||||||||
| DPS(RMB)* | -- | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 3.474 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 3.881B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |